The Ankylosing Spondylitis Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global Ankylosing Spondylitis market has seen substantial growth recently. The market size is projected to increase from $5.9 billion in 2024 to $6.36 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.8%.
The Ankylosing Spondylitis global market is projected to reach $8.71 billion in 2029, growing at a Compound Annual Growth Rate (CAGR) of 8.2%.
Download Your Free Sample of the 2025 Ankylosing Spondylitis Market Report and Uncover Key Trends Now!The key drivers in the ankylosing spondylitis market are:
• Adoption of a personalized medicine approach
• Development of novel biologics
• Emphasis on early intervention and screening
• Lifestyle and diet management, bolstered by telemedicine and remote monitoring
The ankylosing spondylitis market covered in this report is segmented –
1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route Of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users
The key trends in the ankylosing spondylitis market are:
• The trend towards a personalized medicine approach is shaping the market.
• The development of novel biologics is emerging as a trend.
• Focus on early intervention and screening is becoming increasingly prevalent.
• The exploration of regenerative medicine is an emerging trend within the market.
The major players in the ankylosing spondylitis market are:
• Pfizer Inc
North America was the largest region in the ankylosing spondylitis market in 2024